Identification of relevant biomarkers for the aetiology of type 2 diabetes using new genetic concepts


Type 2 diabetes (T2D) causes an increasing global health burden. The pathophysiological processes that cause T2D are chronic and complex. Many recently discovered biomarkers may provide biological clues for T2D. Whether these biological clues are causal or not will provide information to prevent T2D at a very early stage and to develop new targeted personalized interventions in high-risk individuals. Classical association analysis in humans cannot distinguish between cause and consequence. For that, ?Mendelian randomization? is the emerging concept. The idea is that if a biomarker is causally associated with T2D, the genetic variants associated with the biomarker shall also be involved in development of T2D. since genetic variants (a) are randomly assigned to individuals at the time of conception independent from confounders (randomization) and (b) the causal path runs from genes to outcome (T2D) and not the other way around. This strategy will be used to evaluate the causality of recently discovered biomarkers in four large English and Dutch cohorts, which guarantees adequate power and high quality replication of our findings. Second, reverse mendelian randomization on novel genetic variants is used to discover new biomarkers for T2D.


Wetenschappelijk artikel





Dr. A.A. Abbasi

Verbonden aan

Addenbrook's Hospital, MRC Epidemiology Unit, Institute of Metabolie Science


Dr. A.A. Abbasi


31/08/2013 tot 21/03/2016